ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
FDA Approves Adbry® (tralokinumab-ldrm) Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)
New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
ReCode Therapeutics to Participate in May Conferences
ReCode Announces First Participants Dosed in a Phase 1 Study of RCT2100
ReCode Therapeutics to Participate in February Conferences
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration
As green shoots slowly push from the scorched Earth biotech markets, ReCode Therapeutics CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential second half IPO.
ReCode Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy